{"id":"W2943259648","doi":"10.1016/s2352-3026(19)30029-8","title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Agios Pharmaceuticals; European Hematology Association; Stand Up To Cancer; Entertainment Industry Foundation; Celgene; Astex Pharmaceuticals; Van Andel Research Institute; Pfizer; Amgen","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Azacitidine; Internal medicine; Clinical endpoint; Phases of clinical research; Clinical trial; Chronic myelomonocytic leukemia; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001261226,0.0005031262,0.002906792,0.0002978139,0.0001116888,0.00008182982,0.00124913,0.000288427,0.0007980852],"category_scores_gemma":[0.003818411,0.0002729504,0.00006880235,0.0006155972,0.0003827148,0.0002662418,0.0005598853,0.001242884,0.0008349656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000302329,"about_ca_system_score_gemma":0.0005592273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009332674,"about_ca_topic_score_gemma":0.0004091554,"domain_scores_codex":[0.9951319,0.0009548812,0.001202038,0.0009515511,0.000629436,0.001130267],"domain_scores_gemma":[0.993346,0.003900077,0.0006161873,0.00163106,0.0002079629,0.0002986506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9790433,0.003864809,0.004888068,0.0001183356,0.0004802201,0.001686854,0.0009808642,0.00001045288,0.0001201759,0.00004114985,0.006016023,0.002749756],"study_design_scores_gemma":[0.9819606,0.008750103,0.003460153,0.0004868739,0.0004139455,0.0001450223,0.0002045168,0.002895704,0.0001854019,0.00008791934,0.001057698,0.0003520873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875171,0.00008304627,0.00007571009,0.002260197,0.0007118981,0.008066001,0.0008868995,0.00009083653,0.0003083637],"genre_scores_gemma":[0.9954189,0.000175987,0.001061909,0.0008160183,0.0003525215,0.0003610163,0.001000609,0.00008957578,0.0007234294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007901886,"threshold_uncertainty_score":0.9999723,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04404335895220433,"score_gpt":0.3505637352000422,"score_spread":0.3065203762478379,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}